John Parkinson

The federal agency sent a checklist and priority list to all 50 states and 5 large American cities as it prepares for vaccine approval.

The test designed to detect SARS-CoV-2 will be available in Europe later this month and provides results in 15 minutes.

The company is recruiting up to 30000 Americans for AZD1222, its vaccine candidate, as it enters a late-stage trial.

FDA expands usage to all hospitalized COVID-19 patients.

ARCC made the announcement yesterday that the WHO African Region is free of the virus.

ViiV Healthcare’s dolutegravir/lamivudine (Dovato) may be potential treatment option for this patient population

Company says investigational therapeutic could afford at least 6 months of protection from the virus.

This could be an important feature in potential vaccine development.

Regeneron will distribute a prospective therapy in the US and Roche will be responsible for it internationally.

The IDSA recommends against its use in the hospital setting.

The vaccine candidate, BNT162b2, was well-tolerated and phase 3 enrollment is more than one-third complete.

In unexposed blood samples, investigators discovered memory helper T cells that recognize cold coronaviruses also recognized SARS-CoV-2, and may help people fight off the virus.

ViiV Healthcare’s recent FDA approval of expanding a combination antiretroviral comes on the heels of the important data from the TANGO study.

In a small study, preliminary analysis shows patients given this treatment early in hospitalization showed improvement and reduced mortality rates.

The pharmaceutical company has over 25% more US doses due to the increased anticipation of higher demand because of COVID-19.

Two Boston physicians using Interleukin-6 inhibitors report a reduction in intubation and mortality rates.

A new survey shows parents’ fears of getting kids to their providers for fear of contracting the virus.

US government has purchased this batch of vaccines, which Moderna will manufacture concurrently with its phase 3 trials.

RLF-100 is an investigational therapy granted an FDA IND this week and looks to treat moderate and severe cases of COVID-19.

Investigational therapy, RLF-100, is being studied with the goal of preventing progression to respiratory failure.

This finding suggests large disparities in kids and echoes adult population positive rates.

The Novavax NVX-CoV2373 vaccine candidate is shown to be well-tolerated and elicited antibody response.

Two studies will investigate monoclonal antibody-based treatments in both patients with mild disease and those who are hospitalized.

An understanding of what one country saw earlier this year and the prospect of what other countries can do for future openings.

A New York City cardiologist talks about the presentation of patients with severe COVID-19 who experienced this condition.

After review of 2 randomized trials, a panel of health care providers and patients see limited benefit for the medication.

Medha Munshi, MD, discusses the specific challenges of the quarantine and how she was able to help her patients with diabetes comply with their care.

Manufacturers announce their supplies are being sent out for the upcoming season.

GSK, Sanofi were selected by US Operation Warp Speed to provide a large supply.

IDSA, HIVMA request they be included in ongoing COVID-19 clinical trials.